Natalie McGann

发表

CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.

D. Bozyczko‐Coyne, M. Leist, D. Flood, 2005, European journal of pharmacology.

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Allison L. Zulli, R. Parchment, B. Ruggeri, 2007, Molecular Cancer Therapeutics.